Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

58364 1487845784HCLSReviewSingaporeFeb2017.pdf
Energy Boardroom

Blockbuster sales of Insys painkiller raise suspicions of off-label marketing

14.05.2014 / Fierce Pharma

When Insys Therapeutics won approval for its new narcotic painkiller, Subsys, in 2012, few predicted the product would find much of a market, because the FDA limited its use to cancer patients who were already on powerful painkillers. But in 2013, the product raked in $96 million in sales, and the company's stock price quintupled to $25 a share.

Cover_HCLS_Singapore LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: